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Abstract
There are currently seven approved immune checkpoint inhibitors (ICI) 
for the treatment of various cancers. These drugs  are associated with 
profound, durable responses in a subset of patients with advanced cancers. 
Unfortunately, in addition to individuals whose tumors show resistance, there
is a minority subgroup treated with ICIs who demonstrate a paradoxical 
acceleration in the rate of growth or their tumors – hyperprogressive disease.
Hyperprogressive disease is associated with significantly worse outcomes in 
these patients. This phenomenon,  though still a matter of dispute, has been 
recognized by multiple groups of investigators across the globe and in 
diverse types of cancers. There are not yet consensus standardized criteria 
for defining hyperprogressive disease, but most commonly time-to-treatment
failure less than two months and an increase in pace of progression of at 
least two-fold between pre-immunotherapy and on-treatment imaging has 
been used. In some patients, the change in rate of progression can be 
especially dramatic – up to 35- to 40-fold. MDM2 amplification and EGFR 
mutations have been suggested as genomic correlates of increased risk of 
hyperprogression, but these correlates require validation. The underlying 
mechanism for hyperprogression is not known, but warrants urgent 
investigation.
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Key Points
 Hyperprogressive disease, reflecting a marked acceleration in tumor 
progression, after immune checkpoint blockade can occur in diverse 
cancer types and is associated with ~3-month overall survival
 Relative frequency of hyperprogressive disease after immune 
checkpoint blockade ranges from <5% to 29%
 MDM2 amplification and EGFR alterations have been associated with 
hyperprogressive disease, but these genomic markers and their 
mechanism of action require validation in larger datasets.
 A change in pace of progression between pre-immunotherapy and on-
treatment imaging is important to differentiate between patients who 
have accelerated progression on immunotherapy versus those who 
have an aggressive disease regardless of treatment.
Immunotherapy in the form of checkpoint blockade has resulted in 
impressive responses for several previously refractory tumor types. Indeed, 
the Food and Drug Administration (FDA) has now approved seven checkpoint
inhibitors: pembrolizumab, nivolumab, durvalumab, avelumab, atezolizumab,
cemiplimab, and ipilimumab.1-7 Immune checkpoint inhibitors (ICIs) mediate 
responses by reactivating the immune system.  Reactivation occurs because 
these antibodies interfere with checkpoints such as programmed death-
ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
that have been exploited by tumor cells to evade the immune response, a 
necessity if the cancer is going to survive.8 The FDA approvals 
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notwithstanding, there are now multiple groups who have reported that a 
minority of patients (albeit encompassing diverse cancers), experience a 
dramatic acceleration in the rate of tumor progression after starting 
checkpoint blockade, --  a phenomenon designated hyperprogressive disease
(HPD) (Table 1).9-20 Unfortunately, in the patients who are deemed to have 
HPD, their median overall survival (OS) is estimated to be roughly three 
months.21 
The phenomenon of enhanced progression after checkpoint blockade 
has been described with different checkpoint blockade agents and in 
numerous tumor types including, but not limited to, non-small cell lung, head
and neck, breast, gastric, and genitourinary cancers.9-16,18-23 The fact that 
various histologies that can be afflicted by HPD suggests that there could be 
common, histology-agnostic biologic/molecular mechanism(s). A final reason 
for the controversy around the existence of HPD may be the reluctance of 
physicians and other stakeholders to acknowledge that therapies like 
checkpoint blockade could make some patients worse.  Indeed, despite HPD, 
our impression remains that immune checkpoint inhibitors are some of the 
most effective drugs ever brought into the clinical cancer arena, with 
transformative activity in a broad range of lethal malignancies, including 
long-term complete remissions in some individuals with highly refractory 
disease and heavy disease burden. For this reason, HPD should be 
considered “a toxicity,” or an immune-related adverse event (irAE)  similar to
other potential side effects, and should not restrict the use of these 
important agents.   Even so, there is an urgent imperative to inform patients 
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of the risk of HPD, to determine the predictors of this phenomenon, and to 
unravel its underlying biology.
The frequency of HPD after immunotherapy varies depending on the 
publication, ranging from <5% to 29% (the latter reported in one study of 
head and neck squamous cell carcinoma). 9-16,21-23 One question that arises is 
whether or not HPD is unique to immunotherapy. One report suggests that 
HPD after chemotherapy can occur, albeit at a much lower rate of 5.1% 
(3/59) (versus ~14% after checkpoint blockade in that study).15 
A key debate regarding the existence of HPD is whether or not the 
cancer was an aggressive one in the first place, with the thought being that 
rather than an induced immunologic effect, the aggressive growth is merely 
a lack of effective therapy (Figure 1). In this regard, there are varying 
criteria that have been proposed to define HPD (Table 1). For instance, 
Champiat and colleagues9 define HPD as RECIST progression after first 
evaluation and ≥2-fold increase of the tumor growth rate between the 
reference (prior) and the experimental periods; Kato et al10 defined HPD as 
>50% increase in tumor burden while on checkpoint blockade compared 
with pre-immunotherapy, with a <2-month time-to-treatment failure (TTF) 
and a >2-fold increase progression pace.10 Importantly, the latter requires 
scans approximately two months before starting immunotherapy to be 
compared to pre-immunotherapyscans, to exclude the possibility that the 
tumor had an aggressive pace of growth even before starting 
immunotherapy. Virtually all other research groups have almost identical 
definitions for HPD (Table 1) except for Matos Garcia et al13 and Lo Russo et 
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al.18 The first group used the following definition: TTF <2 months and 
increase in measurable lesions of >10 mm plus the following: (i) increase of 
≥40% in target tumor burden compared to pre-immunotherapy; or (ii) 
increase of ≥20% in target tumor burden plus multiple new lesions. The 
second group used a similar definition, and patients with HPD had to fulfill at 
least three of the following clinical/radiological criteria: (i) TTF < 2 months  
(ii) increase ≥50% in the sum of target lesions major diameters between 
baseline and first radiologic evaluation; (iii) appearance of at least two new 
lesions in an organ already involved between pre-immunotherapy and first 
radiologic evaluation; (iv) spread of the disease to a new organ between pre-
immunotherapyand first radiologic evaluation; (v) clinical deterioration with 
decrease in Eastern Cooperative Oncology Group (ECOG) performance status
≥ 2 during the first 2 months of treatment. To avoid attributing rapid 
progression to immunotherapy when it simply reflects aggressive disease, 
some have argued that criteria that identifying HPD include a comparison to 
a pre-baseline time period (perhaps ~2 months) to demonstrate a 
substantial change in pace of tumor growth. Even this may not be valid, as 
patients are often on therapy during the period preceding initiation of 
immunotherapy. Further, this strategy could be difficult to apply when 
immunotherapy is administered in first line; therefore, validation of surrogate
criteria that do not include a pre-baseline scan will be an important future 
effort.
Despite the controversy around the existence of HPD, unique response 
patterns after checkpoint blockade are not new.24,25 For instance, a 
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phenomenon termed pseudoprogression has been well established after 
checkpoint blockade, albeit in a small subgroup of patients.25-27 
Pseudoprogression is defined by the appearance of progression on scans, 
probably because of immune infiltration, but the patient is asymptomatic or 
feels better (in contrast to hyperprogression where the patient, in our 
experience, feels worse) (Figure 1). Furthermore, with pseudoprogression, 
scans ultimately show tumor response. Forms of pseudoprogression have 
also been previously described, albeit rarely, with agents outside of 
immunotherapy, e.g. after glioblastoma treatment and with some targeted 
therapeutics.28-30   The relatively unique response patterns after checkpoint 
blockade have resulted in development of modified RECIST criteria for 
immunotherapy—i.e., iRECIST.31,32 Importantly, with iRECIST, new lesions are 
assessed as per RECIST 1.117, but are recorded separately (and not included 
in the sum of target lesions identified at baseline).  This type of evaluation 
results in a new category of unconfirmed progression (iUPD). Confirmed 
progression (iCPD) is only assigned if, at the next imaging, an increase in the
size of new lesions is seen or additional new lesions appear.
Because of the urgency associated with the rapid progression that is 
the hallmark of HPD, it is crucial to differentiate between hyperprogression 
and pseudoprogression as early as possible, even before re-imaging. With 
the former, checkpoint blockade should be immediately stopped; in contrast,
with the latter, treatment should be continued. Liquid biopsies that 
interrogate serial blood-derived circulating cell-free DNA (cfDNA) may be 
useful in this regard.  It appears, at least based on one small study, that the 
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genome instability number in cfDNA rises precipitously with 
hyperprogression, but falls with pseudoprogression, when measured at about
three to six weeks after starting immunotherapy.33
Another key question in HPD is whether there are clinical or molecular 
features that are associated with an increased risk of accelerated growth 
after checkpoint blockade. Predictors of HPD have included age ≥65 years 
old, female gender, regional recurrence of disease, having more than two 
sites of metastases, low baseline highly differentiated CD4+ T cells or 
effector memory CD8+ T cells, high severely exhausted T cells or 
proliferating T regulatory cells , clustered CD163+ PD-L1+ CD33+ 
macrophages with epithelioid morphology as well as genomic markers 
(mainly MDM2/MDM4 alterations and EGFR alterations) (Table 1).9-16,18-20,22 
There are inconsistencies between studies in that some have not shown age 
or sex to be predictors. Further, while described by several groups including 
ours, 10,12,19,34 the putative genomic correlates (e.g., MDM2/MDM4 and EGFR 
alterations) require larger sample size validation, and an understanding of 
potential mechanisms by which these alterations could mediate or facilitate 
accelerated tumor growth after checkpoint blockade. 
Despite the current uncertainty regarding molecular markers such as 
MDM2 amplification and EGFR alterations that may predict HPD9,12,34, the use 
of genomic aberrations as biomarkers for immunotherapy response pattern 
has been previously established.35-41  Indeed, although genomics and 
immunotherapy are often considered as separate fields, in reality, they are 
tightly linked.42 There are various genomic aberrations that correlate with 
8
immunotherapy response include (but are not limited to): (i) mismatch repair
gene defects that result in microsatellite instability high (MSI-H); (ii) high 
tumor mutational burden (TMB-high); (iii) PBRM1 and CDK12 mutations; and 
(iv) PD-L1 amplification.35-41 Other biomarkers such as high PD-L1 protein 
expression, gut microbiome, as well as POLE43, ATM44 (TMB-mediated), ATR45 
(TMB-mediated), and CDK1246 mutations which have been shown to predict 
response to immunotherapy.33,47-49  Of interest in this regard, pembrolizumab 
was granted the first tissue-agnostic approval by the FDA in patients with 
mismatch repair gene-altered/MSI-H solid tumors of any type, based on 
response rates of ~40%.1 The reasons that MSI-H and TMB-high predict 
response to immunotherapy are probably related, since MSI-H almost 
inevitably leads to a high TMB.50 TMB-high means that there are likely many 
neo-antigens produced by the tumor mutational genome and, hence, a 
greater chance that the reactivated immune system post-checkpoint 
blockade will be able to differentiate the neoplasm from normal tissue 
elements and target it for eradication.51,52 In certain tumor types, such as 
clear cell renal cell carcinoma, PBRM1 mutations have been associated with 
response to immunotherapy.35,40 PBRM1 encodes a subunit of the PBAF 
switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, 
which regulates how tightly DNA is packaged in cells; its loss may increase 
expression of T cell cytotoxicity.35,40 Similarly PD-L1 amplification in Hodgkin 
lymphoma and various solid tumors also associates with immunotherapy 
benefit.39,53,54 There are also several markers of tumor resistance, again of 
genomic origin: (i) STK11 and KRAS co-mutations in lung cancer55; (ii) loss-of-
function mutations in the genes encoding interferon-receptor–associated 
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Janus kinase 1 or Janus kinase 2, concurrent with deletion of the wild-type 
allele56; and (iii) truncating mutations in the gene encoding the antigen-
presenting protein beta-2-microglobulin (which leads to loss of surface 
expression of major histocompatibility complex class I resulting in attenuated
neo-antigen presentation)56. These observations suggest that genomic 
markers can predict response pattern after checkpoint blockade, and that 
their mechanism of action is not always fully understood, at least initially.
In summary, despite the numerous research teams that have 
documented HPD9-16,18,20-22, the existence of this phenomenon remains a 
matter of dispute. Indeed, an analysis of the OAK trial57, which was a 
randomized study of checkpoint blockade versus chemotherapy in lung 
cancer, did not show a difference in the number of “fast progressors” 
between the arms. However, this trial had no pre-immunotherapy evaluation 
to demonstrate whether or not the pace of progression had increased. 
Patients with rapid progression who do not have pre-immunotherapy imaging
available may be currently difficult to designate as having HPD. Important to 
note however, using pre-immunotherapy imaging may not always be feasible
for all treatment settings; for example, in the first-line setting not all cancer 
patients have available pre-immunotherapy scans. Therefore some groups 
(Table 1)13,18 have suggested criteria for HPD that do not require pre- 
immunotherapy scans; these criteria will need to be validated in patients 
with existing pre-immunotherapy scans. Recent data has shown that HPD 
can be recapitulated in preclinical models.18 As physicians make 
immunotherapy a mainstay of treatment in more cancer types, it will be 
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imperative to develop predictive markers for HPD and to understand the 
biology that underlies this devastating irAE.
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Figure 1. Potential outcomes after initiation of immunotherapy for the treatment of 
various cancers
Time
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Figure Legend: Possible outcomes of treatment with immune checkpoint inhibitors over time. 
Durable response to treatment where target lesions shrink on imaging and remain attenuated 
(green), non-durable response where lesions initially response to therapy, but on subsequent 
surveillance imaging, lesions become resistant  and increase in size (purple), disease progression
where target lesions grow >20% from previous imaging (orange_, pseudoprogression where 
tumors enlarge on imaging initially followed by decrease in size seen (blue), and 
hyperprogressive disease where rapid growth occurs after initiating immune checkpoint inhibitors
(red). 
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Table 1. Criteria for and predictors of hyperprogressive disease (HPD) according to 
different research groups 
Author Criteria for HPD Predictors of HPD
Peer-Reviewed Manuscript
Champiat S et al9 RECIST progression after first 
evaluation and ≥2-fold increase of 
the TGR between pre-
immunotherapy imaging and on-
treatment
≥65 years old
Kato S et al10 TTF <2 months, >50% increase in 
tumor burden compared with 
baseline pre-immunotherapy 
imaging, and >2-fold increase in 
progression pace
MDM2/MDM4 and EGFR alterations
Poor TTF (defined as TTF <2 months) was not 
associated with age, tumor type, Royal 
Marsden or MD Anderson score, or type of 
checkpoint blockade
DNMT3A alterations also significantly 
associated with poor TTF in multivariate 
analysis
Saada-Bouzid E et 
al11 
TGKR calculated as ratio of the slope 
of tumor growth pre-immunotherapy 
and the slope of tumor growth on-
treatment.. HPD was defined as a 
TGKR ≥ 2
HPD seen in 39% of patients with at least a 
locoregional recurrence and 9% of patients 
with exclusively distant metastases.
Ferrara R et al15 Disease progression at the first 
evaluation with change in TGR 
exceeding 50%
More than two metastatic sites prior to 
immunotherapy
Kanjanapan Y et al16 RECIST 1.117 progression at the first 
on-treatment scan and ≥2-fold 
increase in TGR between pre-
immunotherapy and on-treatment 
Female gender  
Lo Russo G et al18 TTF <2 months, increase ≥50% in 
the sum of target lesions major 
diameters, appearance of at least 
two new lesions in an organ already 
involved, spread of the disease to a 
new organ, ECOG performance 
status worse ≥ 2 during the first 2 
mos.
HPD on the basis of 3 concomitant 
out of the 5 possible criteria
Clustered macrophages with epithelioid 
morphology and co-localization of CD163, PD-
L1, and CD33 markers (defined as complete 
phenotype) in HPD cases
Kamada T et al19 TTF <2 months; >50% increase in 
tumor burden compared with pre-
immunotherapy imaging, and >2-
fold increase in progression speed 
(same as per reference 10)
PD-1 blockade facilitated the proliferation of 
highly suppressive PD-1+ effector (CD4+) T 
regulatory cells 
1 of 3 patients with HPD had MDM2 
amplification versus 0 of 18 without HPD
Kim CG et al20 TTF <2 months or ≥2-fold increase 
of the TGR between pre-
immunotherapy and on-treatment 
(same as per reference 9)
HPD was associated with lower frequency of 
effector/ memory (CCR7-CD45RA-) circulating 
CD8+ T cells, and higher frequency of severely
exhausted (TIGIT+PD1+) circulating CD8+ T 
cells
Abstract Only 
Singavi A et al12 Progression at first restaging on-
treatment with increase in tumor 
size >50%, >2-fold increase in TGR
MDM2/MDM4, EGFR, amplifications on 11q13 
(CCND1, FGF3, FGF4, FGF19)
13
Matos Garcia I et 
al13
TTF <2 months and minimum 
increase in measurable lesions of 
10mm plus: 1) increase of ≥40% in 
target tumor burden compared to 
baseline or 2) increase ≥20% in 
target tumor burden plus multiple 
new lesions
HPD was not associated with age, tumor type, 
checkpoint inhibitor regimens, previous 
checkpoint inhibitor or metastatic site 
Kim Y et al14 Defined by TGK pre-immunotherapy 
versus on-treatment (details not 
provided)
No associations found.
Abbreviations: HPD = hyperprogressive disease; IO = immunotherapy; TGK(R) = tumor growth kinetic
(ratio)
TGR, tumor growth rate; TTF = time to treatment failure; 
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